The audio version of this article is generated by AI-based technology. Mispronunciations can occur. We are working with our partners to continually review and improve the results. Provincial court ...

'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. White House responds to Pope Leo’s rebuke of Trump peace plan for Ukraine After winning his ...

This is this week’s ForbesWomen newsletter, which every Thursday brings news about the world’s top female entrepreneurs, leaders and investors straight to your inbox. Click here to get on the ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Nov 14 (Reuters) - Union Pacific (UNP.N), opens new tab and Norfolk Southern (NSC.N), opens new tab shareholders approved a deal to merge both railroad operators, the companies said on Friday. Over 99 ...

Thumbs-down emojis flowed onscreen as Washington-area employees learned they would have to show up five days a week. Their union called the move “callous.” By Shane Goldmacher and Reid J. Epstein The ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

NASHUA — The negotiating teams for the Nashua Teachers’ Union and the Board of Education recently announced a tentative agreement on a new contract covering American sign language interpreters and ...

New Jersey has some of the most bilingual speakers in the nation, according to the latest Census figures. The Garden State ranked third in the nation for the highest percentage of residents aged 5 and ...

Recursion, Roche, and its Genentech subsidiary have unveiled the latest product of their nearly four-year artificial intelligence (AI) drug discovery collaboration, a whole-genome map of specialized ...